We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.04B
AUM Growth
-$32.9M
Cap. Flow
+$22.6M
Cap. Flow %
1.11%
Top 10 Hldgs %
82.41%
Holding
32
New
3
Increased
–
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
CBIO
Crescent Biopharma
CBIO
+$104M
2
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
+$40.2M
3
TRVN
Trevena, Inc.
TRVN
+$29.9M

Top Sells

Rank Stock Value
1
CVT
CVENT, INC.
CVT
+$50.1M
2
ECOM
CHANNELADVISOR CORPORATION
ECOM
+$47.6M
3
GLUU
Glu Mobile Inc.
GLUU
+$23.1M
4
CADX
CADENCE PHARMACEUTICALS, INC COM STK
CADX
+$18.7M
5
SLTM
SOLTA MED INC (DE)
SLTM
+$8.44M

Sector Composition

Rank Sector Weight
1 Healthcare 50.85%
2 Communication Services 23.71%
3 Technology 16.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRPN icon
1
Groupon
GRPN
$1.06B
$426M 20.92%
2,717,579
– –
TSRO
2
DELISTED
TESARO, Inc.
TSRO
$291M 14.26%
9,854,255
-7,157
-0.1% -$225K
CVT
3
DELISTED
CVENT, INC.
CVT
$217M 10.64%
5,996,212
-1,302,934
-18% -$50.1M
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$158M 7.75%
2,279,781
– –
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$147M 7.21%
6,446,089
– –
CBIO
6
Crescent Biopharma
CBIO
$590M
$140M 6.87%
+85,751
New +$104M
SUPN icon
7
Supernus Pharmaceuticals
SUPN
$2.74B
$95.2M 4.67%
10,650,000
– –
HPTX
8
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$74.4M 3.65%
2,884,221
– –
FIO
9
DELISTED
FUSION-IO INC COM
FIO
$74M 3.64%
7,038,379
– –
MM
10
DELISTED
MILLENNIAL MEDIA INC COM STK (DE)
MM
$56.9M 2.79%
8,224,752
– –
ITMN
11
DELISTED
INTERMUNE INC
ITMN
$44.9M 2.2%
1,341,000
– –
VIRX
12
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$37.3M 1.83%
26,841
– –
RNA
13
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$36.5M 1.79%
+6,480,171
New +$40.2M
WIFI
14
DELISTED
Boingo Wireless, Inc.
WIFI
$30.3M 1.49%
4,467,960
– –
TRVN
15
DELISTED
Trevena, Inc.
TRVN
$30M 1.47%
+6,099
New +$29.9M
NKTR icon
16
Nektar Therapeutics
NKTR
$2.31B
$22.1M 1.09%
121,707
– –
GYRE icon
17
Gyre Therapeutics
GYRE
$639M
$21.7M 1.06%
5,799
– –
ECOM
18
DELISTED
CHANNELADVISOR CORPORATION
ECOM
$21M 1.03%
556,692
-1,104,665
-66% -$47.6M
LXRX icon
19
Lexicon Pharmaceuticals
LXRX
$1.03B
$20.2M 0.99%
1,668,000
– –
DZSI
20
DELISTED
DZS Inc. Common Stock
DZSI
$20.2M 0.99%
956,258
– –
ALIM
21
DELISTED
Alimera Sciences
ALIM
$17.8M 0.87%
150,376
-28,374
-16% -$2.76M
RIGL icon
22
Rigel Pharmaceuticals
RIGL
$715M
$12.6M 0.62%
324,315
– –
OREX
23
DELISTED
Orexigen Therapeutics, Inc.
OREX
$12.6M 0.62%
193,530
– –
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$11.7M 0.57%
5,653,029
– –
EXEL icon
25
Exelixis
EXEL
$14.1B
$7.81M 0.38%
2,207,000
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q1 2014 Portfolio in Review

As of Q1 2014, NEA Management Company held 32 positions worth $2.04B, down 1.6% from $2.07B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

NEA Management Company's Q1 2014 filing shows 3 new, 4 reduced and 4 closed positions. Its largest new stake was Crescent Biopharma: 85,751 shares worth $140M. The largest sale was CVENT, INC., an estimated $50.1M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 38% a quarter earlier, followed by Communication Services and Technology.

  • NEA Management Company's largest Q1 2014 buy was Crescent Biopharma: 85,751 shares worth $140M.
  • NEA Management Company's biggest Q1 2014 reduction was CVENT, INC., cutting an estimated $50.1M.
  • NEA Management Company fully exited Glu Mobile Inc. in Q1 2014, selling an estimated $23.1M.
  • NEA Management Company's ten largest holdings make up 82% of its $2.04B portfolio in Q1 2014.
  • NEA Management Company opened 3 new positions and closed 4 in Q1 2014.
  • NEA Management Company's portfolio value fell 1.6% quarter-over-quarter to $2.04B.

Based on NEA Management Company's 13F filing for Q1 2014, filed 1 May 2014.